Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

KemPharm, Inc. (KMPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.59-0.04 (-0.71%)
At close: 04:00PM EST
5.65 +0.06 (+1.07%)
After hours: 05:07PM EST
Advertisement
Full screen
Loading interactive chart...
  • American City Business Journals

    Meet KemPharm’s new CEO, a West Point grad who will lead the expansion into rare disease drugs

    This Orlando-area expansion means more job creation and investment at KemPharm’s Celebration headquarters.

  • GlobeNewswire

    KemPharm Enhances Senior Management Team

    Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced that it has named Daniel Gallo, Ph.

  • GlobeNewswire

    KemPharm Issues Letter to Shareholders

    CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for

Advertisement
Advertisement